High-Grade Glioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
High-grade gliomas (HGGs) encompass various types of malignant brain tumors, including anaplastic astrocytomas, anaplastic oligoastrocytomas, glioblastoma multiforme (GBM), gliosarcomas, and anaplastic oligodendrogliomas, falling under WHO grades III and IV. They can originate directly from glial cells or from low-grade gliomas that transform into higher-grade malignancies. Patients with HGGs often exhibit a range of symptoms, such as memory dysfunction due to the tumor's invasive nature beyond the enhancing tumor boundaries. These symptoms may or may not aid in pinpointing the tumor's location. Family members and patients frequently recall personality changes and memory loss when discussing the patient's medical history. Headaches and vomiting are typically linked to increased intracranial pressure, with the headache's location being nonspecific. Seizures can be an initial symptom or manifest after diagnosis or during treatment. Neurological deficits correlate with the tumor's location and associated vasogenic edema. High-grade gliomas in children and adolescents are uncommon but tend to display highly malignant behavior, characterized by rapid growth and the destruction of healthy brain tissue. They constitute approximately 15 to 20% of CNS tumors in this age group. These HGGs can be classified based on their location within the central nervous system (CNS), cell of origin, and degree of malignancy. The median survival for patients without any treatment is less than six months, and even with standard-of-care treatment, it extends to only 14.6 months.
- The incidence rate in Europe and North America is approximately 5 per 100,000 person-years. Of these cases, around 70% arenglioblastomas, isocitrate dehydrogenase (IDH)-wildtype or astrocytoma, IDH-mutant, grade 4. Roughly 15% are astrocytoma, IDH-mutant, grade 3, and about 10% are oligodendroglioma, IDH-mutant and 1p/19q deleted grade 3.
Thelansis’s “High-Grade Glioma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential High-Grade Glioma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of High-Grade Glioma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
High-Grade Glioma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment